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1. INTRODUCTION 
 Dendritic cells (DC) are the sentinels of the immune system which cells could be 
founded in all tissues of the healty body. The tissue localization of DCs depends on their 
characteristic phenotypic and functional attributes and the actual activation status of these 
cells. Investigation of the role of the DCs and their functions by Ralph Steimann, Bruce 
Beutler and Jules Hoffmann was awarded with Nobel Prize in Physiology and Medicine in 
2011. DCs are professional antigen presenting cells (APCs) that derive from bone marrow 
hematopoietic stem cells and differentiate to various subsets from macrophage/DC and 
common DC myeloid precursors. The main funcion of the DCs are to connect the functions of 
the innate and the adaptive immunsystem.DCs able to recognize several types of antigens 
owing to wide spectrum of patter recognison receptors (PRR). For an appropriate danger 
signal the DCs can activate, and migrate into the lymph nodes where they can present the 
antigen to the T-lymphocytes.  DCs have a preferential role in the induction and maintenance 
of self tolerance while possessing the unique capability to prime and polarize antigen-specific 
T lymphocyte responses. This series of events can induce cell expansion and polarization of 
effector T-lymphocytes to Th1, Th2, Th17 and Treg directions. 
Human conventional DCs differentiate from CD11c+ blood precursors with or without the co-
expression of CD1a moleculesin vivo and in vitro they could be differentiatedfrom CD14+ 
monocytes isolated from blood in the presence of interleukin-4 (IL-4) and granulocyte-
macrophage colony-stimulatory factor (GM-CSF) therefore several workgroups could 
examine the properties and the potencials of DCs. DCs could be divided into two 
subpopulation based onthe surface expression of CD1a marker, the MHC class I-like CD1a 
belongs to the CD1 family of human membrane proteins, which present pathogen-derived 
non-protein pattern recognition molecules for innate T cells and their expression pattern 
defines DC subsets. The CD1a+ and CD1a- DC subpopulations exhibit distinct functional 
activities and are prone to trigger inflammatory and regulatory type of immune responses, 
respectively. Based on our previous work we hypothetised that the migration of the 
subpopulation of the relaxed or activated DCs differ.  Previous examination shows that DCs 
can secrete both of MMP and TIMP and these play role in the migration ability of the cells. In 
our work we investigated the expression and the secretion of the MMPs and TIMPs in the 
subpopulation of the monocyte derived DCs, and we observe the effect of the GM6001 
synthetics inhibitor of MMPs for the fenotype of the DCs, for the expression and secretion of 
the MMPs and TIMPs, and for the functions of the enzymes.  
 Mesenchymal stromal cells (MSC) are multipotent cells which generally located in the 
bone marrow but can be found in all of the tissues of the body thus MSCs can also be 
obtained from umbilical cord, placenta, muscle, vein wall, peripheral blood or corneal stroma. 
The main function of MSCs to keep undifferentiated niche in the bone marrow through 
inhibiting the differentiation of hematopoetic stem cells (HSC) and play a role in tissue repair 
through their ability for differentiation and immunmodulation, therefore MSCs are considered 
the most promising cell type of tissue engineering and cell based therapies. However, the 
establishment and the production of reproducible, stable and well characterized human MSC 
has remained a challenge hampered by the heterogeneity of tissue-derived MSC. In the 
second period of our study we investigate the effect of the MSC like (MSCl) cells were 
generated from pluripotent HUES9 human embryonic stem cells (hESC) on the phenotype 
and funcions of the DCs, focused on the migration of the relaxed and activated DCs. 
 
1.1. Dendritic cells (DC) 
 DCs continuously circulate from the bloodstream throughout peripheral tissues 
towards draining lymph nodes and upon this patrolling process they can be activated by 
several `activation signals`derived from either exogenous or endogenous stimuli.Resting 
cDCs are localized to peripheral tissues and act as sentinels of the immune system by sensing 
pathogenic or other danger signals. They are characterized by high efficacy of antigen uptake 
and processing associated to low expression of co-stimulatory molecule. Upon antigen 
sampling, relaxedDCs may get activated and become activated DCs while loosing phagocytic 
potential, decreasing antigen uptake and upregulating the expression of MHC and co-
stimulatory molecules, which enable effective presentation of the captured antigens to naïve T 
cells in draining lymph nodes. Thus to fulfill their professional antigen presenting functions, 
activation-driven migration of DCs is a prerequisite of entering lymph nodes and triggering T 
lymphocyte activation.   
 As we mentioned DCs could be divided into two subpopulation based on the surface 
expression of CD1a marker, and the CD1a+ and CD1a- DC subpopulations exhibit distinct 
functional activities and are prone to trigger inflammatory and regulatory type of immune 
responses, respectively. Previous result proved that CDa+ DCs support inflammatory cellular 
immunresponse (Th1) and CD1a- DCs play role in tolerogen humoral immun response (Th2), 
based on these findings, in the first part of our study we examine the migration of the 
subpopulations of the DCs. 
 Cell migration is a complex process that involves multiple steps. Conventional DC 
continously take up and internalize antigens by using a wide spectrum of pattern recognition 
receptors (PRR) as Toll-like receptors (TLR) cytosolic NOD-like receptors (NLR) and Rig-
like receptors (RLR). RIG-I and MDA5 are effective mitochondrial RLRs wich are 
responsible for recognizing ssRNA, dsRNA and DNA viruses and for antiviral immune 
response. Upon sensing endo- or exogenous danger signals DC become activated and migrate 
into the draining lymph nodes where they present their antigenic cargo to naïve T-
lymphocytes.Chemo-attractants are essential to define the direction of cell migration, 
adhesion molecules help to lie the anchors, and proteinases are involved in the degradation of 
the extracellular matrix (ECM) to support the route of cell migration.Encounter of 
conventional DC with naïve T-lymphocytes depends on the timely migration of activated DC 
to the draining lymph nodes driven by the CCR7 chemokine receptor expressed by stimulated 
DC, as well as by the expression of the CCR7 chemokine receptor ligands CCL19 and/or 
CCL21. We have previously shown that functionally active Nav1.7 is predominantly 
expressed in resting DC but its expression is decreased in parallel with DC activation thus 
providing a sensitive tool for correlating the state of DC activation to Nav1.7 channel activity. 
Our previous studies also demonstrated that the low expression level of the Nav1.7 ion 
channel, in combination with the high expression of CCR7, is the pre-requisite of DC 
migration from the site of inflammation to the lymph nodes. 
 This receptor-ligand interaction up-regulates the expression of matrix 
metalloproteinases (MMP), responsible for the degradation and remodelling of the 
extracellular matrix upon cell migration, while the proteolytic activity of MMP is regulated by 
the tissue inhibitors of MMP enzymes (TIMP). Maintaining the balance between these 
opposing activities MMP and TIMP are crucial for preventing uncontrolled enzymatic 
degradation of the extracellular matrix known to contribute to the initiation of inflammation, 
autoimmune disorders and cancer metastasis.   
 
1.2. Matrix metalloproteinases 
 30% of the proteins of the human body are collagens which could be found in the skin, 
bones and connective tissues as the extracellular matrix or basement membrane. ECM 
continously renew and transform duringstructural and biochemical support to the surrounding 
cells.Matrix metalloproteinases (MMPs) belong to a large family of zinc and calcium ion-
dependent enzymes, which are able to degrade ECM components, thus playing important 
roles in ECM remodeling, angiogenesis, wound healing, and driving cell migration.Several 
cell type are able to secrete MMPs and the Tissue Inhibitors of MMPs (TIMPs).The balance 
of MMP and TIMP is also known to have an impact on cell migration, homeostasis, survival 
and other functional activities of immune cells via regulating the cleavage of extracellular 
matrix components (ECM) to generate soluble cytokines, chemokines and growth factors 
together with their matching receptors.Upon these steps, MMPs may acquire the capacity to 
cause overt tissue destruction unless their activity is not regulated tightly by tissue inhibitors 
of MMPs (TIMPs). Thus imbalances in the activity of MMP and TIMP genes and proteins 
have an impact on inflammatory and autoimmune disorders and on cancer metastasis.  
As we mentioned the regulation of MMPs is excessively important because the substarte 
specificity of these enzymes are overlapping. The activated MMPs could be inhibited by 
internalisation, natural or synthetics inhibitors, but the most important inhibitors are the TIMP 
which directly obstruct the enzyme activity of MMPs.TIMPs family have 4 members which 
could bind in 1:1 ratio. They are subdivided into an N-terminal and a C-terminal 
subdomain. During the inhibition the N teriminal aminoacid of the TIMPs bind the active site 
of the MMPs occupy it from the substrate. 
 
1.3. DCs and MMPs 
 Relaxed and activated monocyte-derived DCs express, produce and secrete 
functionally active MMPs and TIMPs and their expression levels and spontaneous migratory 
capacity have been shown to be upregulated in multiple sclerosis. The elevated migratory 
capacity of activated DCs was attributed to MMP-9, the activity of which could be inhibited 
by TIMPs, and the concomitant decrease of endogenous TIMP levels was also described. 
Furthermore, MMP-2 and MMP-9 were reportedly expressed in skin DCs but not in other DC 
types. Monocyte-derived DCs express membrane type 1 MMP on their cell surface, which 
was shown to play a role in cell migration. Prostaglandin E2 (PGE2), an important stimulator 
of DC migration also induced TIMP-1 but not MMP-9 expression in DCs and was correlated 
to reduced migration through the ECM. In contrast to these data, other groups found that 
PGE2 accumulated in inflamed tissues upregulates the expression and secretion of membrane-
bound MMP-9. DC-derived MMP-9 also seems to be essential for DC chemotaxis in response 
to the CCR7 ligand MIP-3β.  
 These results indicated that the disruption of the delicate MMP/TIMP balance, 
observed in several pathological conditions including osteoarthritis, atherosclerosis, 
aneurysm, pulmonary emphysema, neurodegenerative diseases and cancer, is involved in the 
regulation of inflammation and cell migration. Consequently, the development of synthetic 
MMP inhibitors with high potency and selectivity has a great impact on the progression and 
outcome of inflammatory diseases.The synthetic drug GM6001, also known as Ilomastat or 
N-[(2R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan methylamide has 
been identified as a potent inhibitor of collagenases and results in the inhibition of MMP 
activity, which leads to reduced matrix remodeling. 
In this study we aimed to analyze the expression and functional importance of MMPs and 
TIMPs in human monocyte-derived DC migration. 
 
1.4. Mesenchymal Stromal Cell like cells (MSCl) regulate the phenotype and the 
functions of DCs 
 MSCs are multipotent cells located primarily in the bone marrow, MSCs can also be 
obtained from umbilical cord, placenta, muscle, vein wall, peripheral blood or corneal 
stroma.The main function of MSCs are i) to maintain the bone marrow niche for the 
undifferentiated cells by inhibiting the differentiation of hematopoetic stem cells (HSC) 
through a direct cell-cell contact and release of galectin-1, angiopoetin-1, osteopontin, 
thrombospondin -1 and -2 and others, and ii) to play a role in tissue repair through their ability 
for differentiation and immunomodulation. Therefore MSCs are considered as the most 
promising cell type of tissue engineering and cell-based therapies.  Several studies reported 
the effect of the MSCs for the cell division of the T and B lymphocytes and DCs where MSCs 
inhibit the cells to get to G0/G1 phase from S phase. The first description of successful 
experiments with intravenous infusion of haploidentical MSCs against graft vs host disease 
was published in 2004 by Le Blanc et al and recently, methods using MSCs have been 
reported in more than 50 clinical trials ( www.clinicaltrials.gov)  However producing a 
reproducible, stable, well characterized human MSC line is still a challenge because of the 
heterogeneity of the isolated tissue-derived MSCs.  
 Several studies made an attempt to characterize MSC-like cell lines (MSCl) from 
different tissues. Here we use MSCl cell line generated from pluripotent HUES9 human 
embryonic stem cells (hESC) which originally provided by Douglas Melton, Harvard 
University. The phenotype, morphology and functional characteristics of the cell line have 
been shown to be stable for more than 15 passages. MSCl cells express the typical cell surface 
markers of MSCs (CD44, CD73, CD90, CD105) but they are negative for hematopoietic 
(CD34, CD14, CD133, CD45) and embryonic markers (Oct4, Nanog, ABCG2, PODXL, 
SSEA4). MSCl cells are able to differentiate to osteogenic, chondrogenic or adipogenic cell 
lineages similarly than BM-MSCs and exhibit the most important MSC property that they 
support undifferentiated growth of hESCs as a feeder cell line,therefore MSCls can be used as 
a model of human MSCs. Moreover, MSCls can be generated in unlimited number from 
hESC and it could also be the ideal cell line with self-renewal capacity and with the 
immunosuppressive properties of MSCs to transplant. 
MSCs modulate the innate and adaptive immune responses by affecting the functions of T and 
B lymphocytes, natural killer cells and dendritic cells (DC). MSCs are able to suppress the 
differentiation, activation, migration and antigen presentation of the conventional DCs (, a cell 
population important in connecting innate and adaptive immune responses through presenting 
antigen to the naive T lymphocytes and inducing their proliferation. 
Q. Wang et al demonstrated that BM-MSCs could shift from proinflammatory T-helper-1 
(Th1) to anti-inflammatory Th2 immune response in murine, which observation strenghten 
the relevance of the MSCs in clinical methods when inhibition of the immune response 
required as in transplantation, contact allergy and autoimmune disorders. As we mentioned 
DCs are able to recognize several types of antigens via a wide spectrum of pattern recognition 
receptors (PRR). Upon sensing danger signals DCs become activated and migrate into the 
lymph nodes where they present antigens to T lymphocytes. DCs activated through Rig-I 
secrete inflammatory cytokines. Recently, it has also been shown that Rig-I is fully functional 
and plays an important role in the survival of MSCs.  
As it is clear the DC-T cell encounter requires the migration of activated DCs from the 
periphery to the lymph nodesdriven by CCR7 chemokine receptor expressed on the cell 
surface of mature DCs and theproduction of the CCR7 ligand CCL21 in the lymph nodes and 
this interaction regulates the expression of MMP and TIMPsduring cell migration.  
Chemokine-stimulated migration of the activated DCs is regulated by the expression of the 
voltage gated sodium channel Nav1.7, which expression is decreased during the activation of 
the DCs and it was higher in the CD1a+ subpopulation. 
In this communication we investigated the effects of MSCl cell line on DC activation by Rig-I 
focused to the circustance of changes of the functions and migration of the cells.
2. AIM OF THE STUDIES 
#1 
 Characterize the expression and the secretion of the MMPs and TIMPs during the 
differetiation of the DCs by IL-4 and GM-CSF 
 Characterize the expression and the secretion of the MMPs and TIMPs during the 
activation of the DCs by inflammatory cocktail or LPS 
 Compare the expression of the MMPs and TIMPs in the CD1+ and DC1a- 
subpopulations of therelaxed and cocktail activated DCs 
 Detect the effects of the GM6001 sytethicsinhibitor of MMPs to the phenotype and 
functional activities of the DCs 
 
#2 
 Examine the effect of the MSCl cells for the phenotype of the activated DCs by poly 
(I:C), 5’pppRNA and inflammatory cocktail 
 Investigate the cytokine and chemokine secretion of the activated DCs by poly(I:C) 
and 5’ppRNA in the presence of MSCl cells 
 Detect the T cell proliferation by poly(I:C) and 5’pppRNA activated DCs cocultured 
with MSCl cells 
 Examine the circumstances of the migration of cocultured DCsin the presence of 
MSCl cells 
 Detect the expression of RIG-I, MDA-5 and LGP2 intracellular receptors of the DCsin 
the presence of MSCl cells 
  
 3.  MATERIALS AND METHODS 
3.1. Generation of monocyte-derived dendritic cells (DC) 
 Monocytes were separated from peripheral blood mononuclear cells (PBMC) of 
healthy donors drawn at the Regional Blood Center of the Hungarian National Blood 
Transfusion Service (Debrecen, Hungary). PBMCs were obtained using Ficoll Pacque Plus 
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden) gradient centrifugation followed by 
positive selection of CD14+monocytes using anti-CD14-coated magnetic beads (Miltenyi 
Biotec, Bergisch Gladbach, Germany). Monocytes were plated at 2x106 cell/ml concentration 
in AIMV (Gibco, Paisley, Scotland) or in the case of coculture studies in RPMI (Hyclone, 
South Logan, Utah) supplemented by10% FCS (Gibco, Paisley, Scotland) and 
1%antibiotics/antimycotic solution (Hyclone, South Logan, Utah) in the presence of 100 
ng/ml IL-4 and 75 ng/ml GM-CSF (Peprotech EC, London, UK) given on days 0 and 2. 
 
3.2. Generation of mesenchymal stromal cell-like cells (MSCl) 
 Mesenchymal stromal cell-like cells (MSCl) were generated and characterized in the 
laboratory of Balázs Sarkadi at Semmelweis University, Budapest, Hungary, originated from 
human embryonic stem cell lines HUES9 and HUES1 provided by Douglas Melton, Harvard 
University, Boston, USA. MSCl cells were cultured and passaged in opto-mechanical-treated 
polystyrene flasks (TPP, Trasadingen, Switzerland) in low glucose DMEM (Hyclone, South 
Logan, Utah) in the presence of L-glutamine, 10% FCS and 1% antimycoticum/antibioticum 
solution (Hyclone, South Logan, Utah). MSCl cells were used after 10 passages. 
 
3.3. Co-culture of DCs and MSCls 
 MSCl cells were collected using Trypsin/EDTA 0.05%/0.02% solution in DPBS, 
washed and cultured at 4x105 MSCl cells/six well plate in 8.9 cm2/well area (TPP, 
Trasadingen, Switzerland) in 2.5 ml RPMI supplemented with FCS and antimycotic/antibiotic 
solution (Hyclone, South Logan, Utah) for a minimum of 6 hour to allow the formation of a 
coherent cell layer.2x106 freshly isolated monocytes were placed directly on the top of the 
adherent MSCl cells and the co-culture was treated with IL-4 and GM-CSF at concentrations 
used for DC differentiation. On the 6th day we separate the cells by CD209 positive selection 
by magnetic beads (DC marker). After the coculture we measure the viability of the cells with 
7AAD by flow cytomerty, we used the cells which viability was up to 92+5% 
 
3.4. Cell activation and GM6001 treatment 
 On day 5 both of the DCs, the MSCl cells and the co-cultured cells were activated 
using an inflammatory cytokine cocktail containing 10 ng/ml TNF-α, 5ng/ml IL-1β, 75 ng/ml 
GM-CSF, 20 ng/ml IL-6 and 1 g/ml PGE2 (Peprotech EC, London, UK), 25 g/ml poly(I:C) 
or 1 g/ml Rig-I-specific 5’ppp dsRNA transfected by Lyovec transfection reagent 
(Invivogen, San Diego, CA, USA) or 500ng/ml lipopolisaccharide (LPS). Cells were 
separated after a 24h activation by magnetic separation of the DCs, based on theirCD209/DC-
SIGN expression (Miltenyi Biotec). 
We treated the DCs with 25 µg GM6001 sytethics inhibitor, and DMSO (solvent of GM6001) 
as a control on 5th day 1h before the activation. 
 
3.5. Phenotyping 
 Phenotyping of the DCs and the co-cultured cells were performed by flow cytomerty 
(BD Biosciences, Franklin Lakes, NJ, USA) and data were analyzed using the FlowJo 
software (Tree Star, Ashland, OR, USA). MSCl cells were identified by the expression of 
CD105-FITC and DCs by te expression of CD209-FITC (BioLegend, San Diego, CA, USA). 
Directly fluorochrome-labeled antibodies against CD80-FITC, CD83-FITC, CD86-PE and 
CD1a-PE along with isotype control antibodies were used to measure the cell surface 
expression of these molecules (BD Pharmingen, San Diego, CA, USA). BD FACS Calibur; 
FITC/ green emission detector, filter: 530/30, PE/ red orange emission detector, filter: 
530/42.CD1a-labeled DCs were separated by using the FACS DiVa high-speed cell sorter 
(BD Biosciences Immunocytometry Systems). 
 
3.6. RNA isolation, cDNA synthesis and quantitative PCR 
 Total RNA was isolated usingTRIzol reagent (MRC, Cincinnati, OH, USA). 2 μg of 
RNA was reverse-transcribed at 37°C for 120 minutes using the High Capacity cDNA 
Archive Kit (Appied Biosystems, Foster City, CA)  and oligo(dT) primers (Promega, 
Madison, WI, USA). Quantitative real-time PCR was performed using gene-specific TaqMan 
assays (Applied Biosystems, Foster City, CA, USA) in a final volume of 12.5 μl, DreamTaq 
DNA polymerase (Fermentas St. Leon-Rot, Germany) and an ABI StepOnePlus real-time 
PCR instrument (Applied Biosystems). The housekeeping gene h36B4 was used to normalize 
the data. Cycle thresholds were determined using the StepOne Software v2.1 (Applie 
Biosystems). 
 
3.7. Cytokine measurements 
 The concetration of MMP-9, IL-12, IFN-γ, CXCL-10, TNF-α, IL-6, IL-8, IL10 and 
IL-1β cytokines were measured by ELISA kits (BD Biosciences, USA) from the supernatans 
of the cell cultures, following the manufacturer’ instructions. Optical densities were 
determined by a microplate reader on 450nm (BIOTEK, Winooski, VT, USA). 
 
3.8. ELISPOT assay 
 Allogen T cells were co-cultured with DCs (previously co-cultured or not with MSCl) 
in serum-free RPMI medium for 3 days at 37°C. INF-γ secreting T cells were detected by the 
avidin-HRP system (NatuTec, GmbH, Germany) and the results were analyzed using the 
ImmunoScan plate Reader (CTL, Shaker Heights, OH, USA). 
 
3.9. Migration assay 
 Migration of DCs and co-cultured DCs were tested using the Transwell system 
(diameter 6.5 mm; pore size 5μm - Corning Inc.,Glendale, Arizona, USA).106DCs were 
added to the upper chamber and the migration assay was conducted with or without the 
addition of 200 ng/ml CCL19 chemokine in the lower chamber. Migrated cells from the lower 
chamber were collected and counted after 24h and 37⁰ of incubation by flow cytometry using 
polystirene beads (Fluka  St. Gallen, Switzerland). 
 
3.10. Gelatinase activity 
 To measure the enzyme activity of MMP9 the InnoZyme™ Gelatinase Activity Assay 
Kit was used (Merck) following the manufacturer`s recommendation. Briefly, supernatants 
were diluted in 1:4 with activity buffer and incubated with gelatinase substrate on 37 oC for 
3h. After incubation fluorescent intensities were measured using the Biotek plate reader. 
 
3.11. Statistical analysis 
 Statistical analyses were performed using T student test in all MMP graphs and 
ANOVA Bonferroni comparison in all coculture experimentts ,the differences were 
considered to be statistically significant at by *P < 0.05; **P < 0.01; ***P < 0.005. The gene 
expression studies of MMP-9, MMP-12, TIMP-1, TIMP-2 show 1 characteristics donor and 
the averaged protein levels was shown. 
  
4. RESULTS  
4.1. Monocyte-derived dendritic cells exhibit characteristic MMP and TIMP 
expression during in vitro differentiation  
Monocyte-derived DCs are migratory cells that change their locations depending on the type 
and level of micro-environmental stimuli. As blood circulating monocytes and DCs 
differentiated from them reside to various peripheral tissues, first we analyzed the expression 
of MMPs and TIMPs in monocytes and monocyte-derived resting/immature DCs. Using high 
throughput affymetrix analysis we monitored the expression pattern of the MMP and TIMP 
family members during the monocyte-to-DC differentiation process. We found that the 
expression of MMP-7, MMP-9, MMP-12, MMP-14, MMP-19, as well as the TIMP-2 and 
TIMP-3 genes were upregulated more than 2-fold in the course of DC differentiation, whereas 
TIMP-1 expression was slightly downregulated in the presence of IL-4 and GM-CSF during 
differentiation. 
To validate the functional importance of these genes we selected MMP-9, MMP-12, TIMP-1 
and TIMP-2 for further characterization. The expression of MMP and TIMP genes showed 
characteristic and dynamic changes in the course of the cytokine-driven differentiation of 
monocytes towards resting and subsequently to activated DCs. The expression levels of 
MMP-9 and MMP-12 were increased, whereas those of TIMP-1 and TIMP-2 were decreased 
during DC development. DC activation by an inflammatory cytokine cocktail further 
increased the expression of these genes as compared to resting cells. In line with the gene 
expression studies, the concentration of secreted MMP-9 protein in the culture supernatant 
measured by ELISA confirmed the increasing expression of the enzyme at the protein level. 
To identify the cytokines involved in these effects we showed that induction of MMP-9 and 
MMP-12 expression in relaxed DC was dependent on GM-CSF but not on IL-4. However, 
full DC activation could be achieved only by the complete inflammatory cytokine cocktail, 
while single cocktail components were able to upregulate MMPs with different efficacy as 
compared to relaxed DCs. Interestingly, downregulation of TIMPs was attributed to the 
synergistic effect of both GM-CSF and IL-4 in relaxed DC, and to the complete inflammatory 
cytokine cocktail in activated DCs. 
Next we tested how DC development and maturation affects MMP and TIMP gene 
expressions in time course experiments. During the monocyte to DC transition process the 
gene expression levels of MMP-9 and MMP-12 were upregulated from 6h to 18h, 
respectively suggesting an indirect GM-CSF-driven gene expression regulation. Changes in 
the expression of the TIMP genes however weredifferent as TIMP-1downregulation started 
after 12h of culture, while decreased TIMP-2 expression was observed as early as1h after 
cytokine treatment. The inflammatory cytokine cocktail induced the upregulation of MMP-9 
and MMP-12 genes 30 minutes after stimulation, and their expression levels peaked at 6-12 h 
indicating a rapid and direct effect of this complex stimulus on DCs. In contrast to these data, 
downregulation of TIMP-1 and TIMP-2 was a slow process that started 6-12 h after DC 
activation suggesting the involvement of indirect effects. These data altogether indicated the 
cytokine-dependent and temporally regulated expression of MMP and TIMP genes. 
Previously we showed that the CD1a- and CD1a+ DC subpopulations express chemokines and 
chemokine receptors differently. To address the question whether the CD1a- and CD1a+ DC 
subpopulations expressed MMPs and TIMPs at different levels, we compared the relative 
expression levels of MMP-9, MMP-12, TIMP-1 and TIMP-2 in sorted cells by Q-PCR. We 
found that in differentiated DCs MMP-9, TIMP-1 and TIMP-2are expressed dominantly in the 
CD1a- subpopulation whereas MMP-12 is preferentially expressed in CD1a+ DCs. In line with 
the gene expression data, MMP-9 is secreted preferentially by activated CD1a- cells. Next, 
using a gelatinase assay, we tested the biologic activity of MMP-9 produced by DCs. 
Wefound that the inflammatory cytokine cocktail-activated DCs produced significantly more 
active MMP than resting cells and it was the CD1a-DC subpopulation that showed elevated 
gelatinase enzyme activity as compared to its CD1a+counterpart. These results clearly 
indicated the DC subtype-specific expression of the previously selected MMP and TIMP 
genes in CD1a- and CD1a+ DCs.  
Based on the validated data MMP-9 is predominantly expressed by activated CD1a- cells, 
whereas MMP-12 shows higher expression level in activated CD1a+ DCs. TIMP-1 exhibited 
high gene expression in both subsets, while TIMP-2 was preferentially expressed by resting 
CD1a- DCs as compared to activated cells. Taken together these results demonstrate the 
differentiation state-dependent expression of MMPs and TIMPs in the course of cytokine-
induced in vitro DC differentiation and also show that the expression of both MMP-9 and 
MMP-12 is induced by inflammatory signals. Interestingly, the expression MMP-9 and 
MMP-12 is biased in the two DC subtypes, however activation-induced MMP enzyme 
expression is ensured in both CD1a-and CD1a+DCs to support DC migration when required.   
 
4.2. The mode of dendritic cell activation affects MMP and TIMP expression 
DCs belong to the first line of defense and are able to recognize conserved foreign and 
dangerous molecules by various pattern recognition receptors (PRRs). DC activation can be 
mimicked by ligands of PRRs so in a further step we used bacterial lipopolysaccharide (LPS), 
recognized by Toll-like receptor 4, to test its effects on the expression of MMPs and TIMPs in 
activated DCs. As shown in fig. 1 and fig. 2 the inflammatory cytokine cocktail was proved to 
be a potent activator of MMP-9 and MMP-12 expression and in parallel induced the 
downregulation of TIMP-1 and TIMP-2. LPS was shown to be less potent to stimulate MMP-
9 and MMP-12 gene expression as compared to the inflammatory cytokine cocktail but was 
able to downregulate TIMP expression. 
Based on these results we conclude that different DC stimulatory signals (inflammatory 
cytokine cocktail versus LPS) are able to modulate the expression of MMPs and TIMPs 
indicating the high sensitivity of this system to inflammatory signals. We suggest that the 
mode and extent of DC activation is an important factor in the fine-tuning of MMP and TIMP 
gene and protein expression. In our hands the four-component inflammatory cytokine cocktail 
was the most potent activator of MMP-9 secretion in activated DCs when compared to LPS-
activatedDCs.  
 
4.3. The synthetic MMP inhibitorGM6001 inhibits the migration of dendritic cell 
subpopulations without modulating their phenotype and functional activities 
After the comprehensive characterization of MMP and TIMP expression in DCs next we 
studied the effects of the broad-spectrum MMP inhibitor GM6001 on DC functions. This 
inhibitor is an extensively used drug for inhibiting MMP-regulated cell migration in different 
therapeutic settings. Treatment of differentiating DCs with 25 μM GM6001 had no effect on 
the gene expression of MMP-9, MMP-12, TIMP-1 and TIMP-2 or on the secretion of MMP-
9. The phenotypic characteristics of GM6001-treated relaxes DCs and activated DCs also 
remained unaffected by the inhibitor as measured by cell surface expression of DC-SIGN and 
the ratio of the CD1a- and CD1a+ cell types. The inhibitor-treated DCs also had no defect in 
the inflammatory cytokine cocktail-induced activation monitored by the cell surface 
expression of the activation molecule CD83 . When the GM6001 MMP inhibitor was added 
directly to the DC cultures and was present during the migration process it was able to inhibit 
the chemotaxis of relaxed DCs and activated DCs toward MIP-1α and MIP-3β chemokines, 
respectively. When the migration of the CD1a- and CD1a+ cells was compared we found that 
the migration of activated CD1a+ cells to both MIP-1α and MIP-3β chemokines was 
significantly inhibited) and MIP-3β-mediated cell migration of CD1a- cells was also 
downregulated by the drug. As the expression of the MIP-3β receptor CCR7 on activated DCs 
was not affected by the inhibitor these data demonstrated that MG6001 acted at the level of 
MMPs and specifically interfered with the functional activity of MMP enzymes in both DC 
subsets. 
 
4.4. MSCl cells inhibit the differentiation and activation of monocyte-derived 
dendritic cells 
Freshly isolated CD14+ monocytes were cultured in the presence of GM-CSF and IL-4 for 5 
days to generate competent DC used as control. Another fraction of DC was differentiated at 
similar conditions together with MSCl cells added at 5:1 monocyte to MSCl ratio present 
throughout the differentiation process. On day 5 both the control DC and the DC co-cultured 
with MSCl cells were activated with poly(I:C), 5’pppRNA or with an inflammatory cytokine 
cocktail containing GM-CSF, IL-1β, TNF-α, IL-6 and PGE2. On day 6 the activated DC were 
separated from the MSCl cells by positive selection of CD209/DC-SIGN expressingcells and 
their proportion was measured in both the control and the MSCl co-cultured cells. This 
procedure resulted in cell populations with >90+5% DC in both the in vitro differentiated and 
MSCl co-cultured cells indicating complete DC differentiation in both cases (data not shown). 
Cell surface expression of CD1a and CD83 membrane proteins, used as indicators of DC 
activation, showed significant decrease when the DC were co-cultured with MSCl cells 
irrespective of the mode of activation induced by poly(I:C), 5’pppRNA or the inflammatory 
cocktail. Interestingly, stimulation of cells in the DC-MSCl co-cultures by the specific RIG-I 
ligand 5’pppRNA resulted in significant up-regulation of the co-stimulatory molecules 
CD80and CD86 on the DC surface as compared to DC cultured without MSCl cells, whereas 
the presence of MSCl cells did not affect the expression levels of these markers in DC 
stimulated by the inflammatory cocktail or by poly(I:C). These results suggest the potential of 
MSCl cells to modulate DC activation and consequently other functional activities.  
 
4.5. MSCl cells modulate the cytokine secretion of activated DC 
To further analyse the functional cross talk of DC and MSCl cells the specific RIG-I ligands 
poly(I:C) and 5’pppRNA were added to the DC- MSCl co-cultures and the secretion levels of 
the pro-inflammatory cytokines IL-6 and TNF-α, the chemokines CXCL8 and CXCL10, as 
well as the T-lymphocyte polarizing cytokines IL-12 and IL-10 were measured in the 
supernatants of the co-cultures. We found that both RIG-I ligands could upregulate the 
secretion of IL-6. CXCL8 and IL-10 in the DC-MSCl co-cultures as compared to activated 
DC and MSCl cells cultured separately. Although IL-10 was present in the supernatants of 
both resting and activated DC at low but measurable levels, we could not detect IL-10 in the 
supernatants of activated MSCl cells. However, the enhanced level of IL-10 in the supernatant 
of the co-cultured and stimulated cells suggest that IL-10 could contribute to the anti-
inflammatory effects of MSCl cells presumably via inhibiting the secretion of pro-
inflammatory cytokines. 
Our results also revealed that the concommitant secretion of TNF-α and CXCL10 did not 
induce a synergistic inflammatory effect but could efficiently be inhibited by MSCl cells 
indicating their potent anti-inflammatory activity. In this experimental system the production 
of IL-12, a key Th1 polarizing cytokine was also dramatically decreased in the presence of 
MSCl cells likely owing to its potential to induce clonal expansion and differentiation of 
IFNγ-producing CD4+ T-lymphocytes. Moreover, IL-12 is able to stimulate the production of 
other inflammatory cytokines such as TNF-α, IFNγ and the interferon-induced chemokine 
CXCL10 to multiply the inflammatory response.  
In line with these results the production of IL-6 and CXCL8, both acting as important 
mediators of tissue repair and angiogenesis, were detected in the supernatants of DC co-
cultured with MSCl cells at increased levels suggesting that they may contribute to create a 
local anti-inflammatory milieu in response to inflammatory signals. These observations also 
imply that beside direct cell-to-cell contacts cytokines and chemokines also could contribute 
to the regulatory functions of MSCl cells. 
 
4.6. MSCl cells interfere with dendritic cell-mediated allogeneic T-lymphocyte 
activation and polarization  
To further analyse the outcome of DC-mediated functional activities in the presence of MSCl 
cells we sought to measure the secretion of IFNγ directly by ELISA and also as a result of 
DC-mediated allogeneic T-lymphocyte polarization by using the ELISPOT assays. Our results 
demonstrated that IFNγ secretion of DC could be induced by both poly(I:C) and 5’pppRNA, 
however the presence of MSCl cells decreased its secretion significantly. The potential of 
poly(I:C) or 5’pppRNA stimulated DC to drive allogeneic T-lymphocyte polarization 
confirmed that MSCl cells are able to interfere with this translational event through exerting 
potent anti-inflammatory effects on DC activation. These results altogether demonstrate that 
DC, upon interacting with MSCl cells, can create an anti-inflammatory local environment. 
 
4.7. The effect of MSCl cells on DC migration 
Previous results demonstrated that efficient presentation of peptide antigens to naive T-
lymphocytes critically depends on the migration of tissue resident DC to the draining lymph 
nodes. As a novel finding our previous studies demonstrated that the low expression level of 
the Nav1.7 ion channel in combination with the high expression of CCR7 is the prerequisit of 
DC migration from the site of inflammation to the lymph nodes. Based on these pieces of 
informations we used a transwell system to study the effects of MSCl cells on the migratory 
potential of DC in the presence or absence of MSCl cells. In this experimental setting the 
upper chamber contained resting DC or DC stimulated either with poly(I:C) or the 
inflammatory cytokine cocktail in the presence or absence of MSCl cells. The lower chamber 
was filled with fresh medium containing 0.5% BSA and the chemokine CCL19/MIP-3β, a 
strong inducer of activated DC migration guided by the membrane bound chemokine receptor 
CCR7. The upper and lower chambers were connected by a membrane of 5 μm pore size to 
allow chemokine driven migration of DC towards CCL19 gradients. The migrated cells were 
collected from the lower chamber and after 24h the number of migrating cells was counted by 
flow cytometry. In correlation with the level of CCR7 chemokine expression in the presence 
of MSCl cells a statistically significant decrease in the number of migratory cells was 
observed. 
Considering that the expression of matrix metalloproteinase enzymes (MMP) and their 
specific inhibitors (TIMP) play impotant roles in regulating DC migration, we also assessed 
the contribution of these enzymes to the regulation of MSCl cell-mediated inhibitory 
functions. Expression of the MMP9, MMP12, TIMP1 and TIMP2 genes, which could be 
induced by the interaction of the CCR7 receptor with its specific ligand CCL19, was 
monitored in both resting and activated DC in the presence or absence of MSCl cells. We 
showed that the expression of MMP9 was upregulated, whereas that of MMP12 was 
dowregulated. The relative gene expression levels of TIMP1 and TIMP2 were higher in 
CD1a- DC than in its inflammatory CD1a+ counterpart and could be associated with a DC 
phenotye similar to cells co-cultured with MSCl cells.  
Another regulatory mechanism that might be involved in regulating MSCl cell-related 
functions could be associated to the activity of the Nav1.7 ion channel. We have previously 
shown that functionally active Nav1.7 is predominantly expressed in resting DC but its 
expression is decreased in parallel with DC activation thus providing a sensitive tool for 
correlating the state of DC activation to Nav1.7 channel activity. When the expression of 
Nav1.7 was measured in activated DC without MSCl cells, the level of Nav1.7 expression 
decreased, even when the cells were stimulated by the inflammatory cocktail or by poly (I:C), 
but it was increased in DC suppressed by MSCl cells. These changes are in good accordance 
with the the low/ undetectable numbers of inflammatory CD1a+ DC detected in these cultures 
as compared to the tolerogenic CD1a- DC subset. 
 
4.8. MSCl cells inhibit the expression of RIG-like receptor family members 
Our results summarized in Figure 1 and 2 show that MSCl cells are potent inhibitors of DC 
functionality induced by the specific ligands poly(I:C) and 5’pppRNA of the cytosolic RIG-
like receptors RIG-I, MDA5 and LGP-2 recognizing dsRNA, ssRNA or DNA. Taking a step 
further we hypothesized that co-culturing DC with MSCl cells might have a direct inhibitory 
effect on the expression of intracellular RIG-I receptors. Indeed, our Q-PCR results revealed 
that mRNA expression of the RIG-I, MDA-5 and LGP-2 receptors belonging to the RLR 
family of cytosolic pattern recognition receptors is up-regulated upon stimulation by specific 
ligands but in the presence of MSCl cells this induction does not occur likely due to the 
inhibited expression of these receptors accompanied by the decreased production of IFNβ. 
Based on these data we conclude that in the presence of MSCl cells the specific ligands of 
RIG-I could not be recognized by DC due to down modulation of RLR receptor expression s 
by MSCl cells.  
 5.  DISCUSSION 
 
 Dendritic cells are constitutive sentinels of the immune system using their capacity to 
migrate between tissues in the body. Thus DCs are increasingly used for immunotherapeutic 
interventions, predominantly in oncology. For example, tumor antigen-charged autologous 
DCs are administered intracutaneously and are expected to migrate to the draining lymph 
nodes to induce local immunity against tumors. This has been shown to happen, albeit at a 
very low efficiency, because the vast majority of DCs remain at the injection site in the skin. 
TNF-related activation-induced cytokines has been shown to increase the number of injected 
DCs that arrive to the lymph nodes in a mouse model and thus it is tempting to speculate that 
the concomitant administration of reagents that activate migration through improved MMP 
function might be of benefit in DC vaccinations. 
 In this work we show that DCs activated by an inflammatory cytokine cocktail 
(containing TNFα) produce elevated levels of MMP-9 and MMP-12 as compared to relaxed 
DCs or DCs activated by LPS. These findings are in good correlation with the migratory 
capacity of these two differently activated DCs, namely the more potent mobility in case of 
cocktail-maturated versus LPS-maturated DCs. More interestingly, we found differences 
between the so-called `inflammatory`CD1a+ and the `anti-inflammatory` CD1a- 
subpopulations of DCs in terms of MMP and TIMP expression patterns. While the CD1a- 
subset mainly expresses and secretes active MMP-9 (gelatinase B), the CD1a+ subpopulation 
expresses MMP-12 (metalloelastase). Moreover, the CD1a- cells are more potent producers of 
TIMPs as compared to its CD1a+ counterpart. These data revealed that in good correlation 
with their migratory capacity, CD1a+ DCs are more mobile cells in terms of both spontaneous 
as well as chemo attractant-induced migratory assays as compared to the CD1a- subtype partly 
because of their elevated production of the endogenous inhibitors TIMPs.   
 To confirm the functional role of MMP-9 in DC migration we used an assay to detect 
its gelatinase enzyme activity. Although the expression of MMP-2, the other member of the 
gelatinase family have been reported in monocyte-derived DCs, others described the 
expression of MMP-2 only in DCs of skin origin. We could not detect MMP-2 gene 
expression in monocyte-derived DCs by affymetrix or Q-PCR thus the elevated gelatinase 
activity observed in activated CD1a- cells could be attributed solely to MMP-9 production. 
High expression of MMP-12 was found to be correlated with multi-system Langerhans cell 
histiocytosis (LCH) with a concomitant expression of CD1a suggesting that this 
metalloelastase plays a role in the progression of LCH. 
  According to our knowledge, this is the first report so far to study the effects of 
GM6001 MMP inhibitor on the phenotypic and functional characteristics of monocyte-
derived migratory DCs. Because of the mechanism of inhibition of GM6001 is to chelate Zn++ 
ions, necessary for MMP functionality, we hypothesized that the GM6001 has no effect on the 
expression and/or the secretion of MMPs and TIMPs in DCs. Based on our data, GM6001 
effectively inhibited the migration of DCs by inactivating the secreted MMPs, without 
affecting the phenotype, differentiation, activation of DCs or modifying the gene expression 
profile of the MMP and TIMP system. The inhibitory activity of GM6001 seems to be 
independent of the expression of CD1a molecules, as effective inhibition has been shown in 
both the CD1a- and CD1a+ subpopulations. Related to this scenario, GM6001 is able to act on 
both MMP-9 and the MMP-12 functions (and possibly on other MMPs not studied in this 
work) expressed by simultaneously differentiating and functionally distinct DC subsets. Based 
on these data the clinical utility of this molecule as an anti-migratory drug has little or no 
unwanted and/or unseen effects on DC biology and can be safely administered to inhibit 
pathological cell migration under inflammatory conditions and/or cancer. 
In addition to the development of syntethic-based therapies, bioengineering and cell therapies 
has been in the center of interest.  
 The unique capability of MSC of different origin to modulate the outcome of 
allogeneic bone marrow transplantation has been pioneered by Le Blanc and her group in 
humans and was confirmed in several mice models. These results also revealed the potential 
of MSC to exert multiple effects on other cell types through regulatory, anti-inflammatory and 
by stander effects and via targeting injured tissues as described in several diseases, such as 
grade IV severe acute GVHD of the gut and liver and steroid resistant severe acute GVHD. 
The utility of MSC also involves the prevention of transplated skin graft rejection, treatment 
of osteogenesis imperfecta by mismatched allogeneic liver-derived MSC in 
immunocompetent fetus, autoimmune encephalomyelitis, diabetes mellitus and collagen-
induced arthritis. Further studies also demonstrated that the anti-inflammatory cytokine 
enviroment created by the transplanted MSC at the site of iflammation is able to improve the 
outcome of acute renal, neural and lung injury. Thus in the past years MSC became clinically 
important cell types due to their regenerative potential that can be utilized in cell therapies 
aimed to treat inflammatory and autoimmune disorders or apply them for tissue engineering. 
 This approach is supported by the unique capability of MSC to bypass MHC 
compatibility for inducing immunosuppression. However, application of these cells for 
therapeutic interventions is limited due to the low number of MSC available. To overcome 
 this restriction several groups also explored new strategies for identifying cell lines with 
immunosupressive properties. A stem cell line, differentiated from a frozen human embryo at 
the blastocyte stage has been characterized.  
 In a pervious collaborative study we described the phenotypic and some functional 
properties as well as the differentiatiating cability of a cell line of embryonic origin with an 
MSC-like phenotpye and we compared its functional activities with BM-MSC and a human 
foreskin fibroblast cell line (HFF). This analysis demonstrated similar morphology, phenotype 
and functional attributes resembling BM-derived MSC and offered us to exploit the further 
functional characterization of these cells in terms of their immunosuppressive potential. Thus, 
the present study is unique in that it provides evidence for the potent immunosupressive 
nature of this MSCl cell line characterized by its profound effects on multiple functional 
properties of resting and activated monocyte-derived DC. 
 Our results performed with human primary DC revealed that MSCl cells could affect 
the maturation, activation and a wide array of functional activities in a similar manner as 
human BM-MSC. As a consequence, the phenotype of DC was modified in the presence of 
MSCl cells resulting in decreased expression of the CD1a and CD83 activation markers on 
the surface of activated DC induced by an inflammatory cytokine cocktail or by specific 
ligands of the RIG-I receptors. A similar effect was decribed in LPS-induced activation of 
mice in the presence of BM-MSCs and TNF-α induced stimulation of umbilical cord blood or 
bone marrow derived MSC. In contrast, the expression of the CD80 and CD86 costimulatory 
molecules was upregulated in the human DC-MSC co-cultures, while in mice the expression 
of these molecules was decreased in the presence of both murine and human BM-MSC 
indicating species related differences in the inhibitory function of MSC. Changes in the 
cytokine secretion by DC in the presence of MSC of various origins have also been 
demonstrated however, the mechanistic backtround of this regulation has not been explored. It 
was also shown that MSC, isolated from mouse embryonic fibroblasts could induce the 
generation of IL-10-dependent regulatory DC via SOCS3 activation leading to increased 
secretion of anti-inflammatory IL-10.  
 The cytokines IL-6 and CXCL8 have been considered as important mediators of tissue 
repair and angiogenesis. In LPS stimulated DC the presence of MSC could increase the 
secretion of IL-6 and CXCL8 and in response to poly(I:C) or 5’pppRNA increased secretion 
of IL-6, IL-10 and CXCL8 was also detected opposing the significantly decreased levels of 
IL-12 and TNF-α in the supernatant of the DC-MSCl co-cultures. These results suggest that 
the contact and/or the communication of cells and soluble factors may trigger anti-
 inflammatory and/or healing mechanisms that shift the balance of the response to tissue 
regeneration and changes in cytokine and chemokine secretion.  
The CCL19 chemokine is expressed in the thymus and lymph nodes and its secretion is 
essential for the migration of CCR7high DC to the draining lymph nodes where they interact 
with naive T-lymphocytes. However, the expression of CCR7 and the migration DC derived 
from the DC-MSCl co-cultures exhibited significantly decreased migration as compared to 
DC cultured in the absence of MSCl cells. One of the mechanisms involved in this complex 
regulation was discovered recently showing the contribution of the voltage gated membrane 
channel Nav1.7, which regulates intracellular Ca2+ concentration in DC and also acts as a 
master regulator of the cell cycle. High intracellular Ca2+ concentration was shown to be 
essential for DC activation and was associated with downregulated Nav1.7 expression. As 
anticipated, the expression of the voltage gated sodium channel Nav1.7 was also dramatically 
down modulated and could be used as a sensitive indicator of the DC activation state. 
 Although Nav1.7 expression was maintained in the presence of MSCl cells, these 
results indicate that high intracellular Ca2+ concentration seems to support Nav1.7 expression 
and channel activity, but interferes with DC activation. Overall, these data indicate that in the 
presence of MSCl cells the generation of DC results in „semi-activated” Nav1.7high and 
CCR7low cells, which express high amounts of active MMP9 enzyme and also TIMP with 
inhibitory potential to induce the dramatically reduced migartory potential of DCs. 
Upregulation of CXCL8 chemokine was shown to support the expression of MMP-2 and 
MMP-9 in throphoblast cells. The balance of MMPs and TIMPs is known to have an impact 
on the migration, homeostasis, survival and other functional activities of immune cells via 
regulating the cleavage of extracellular matrix components (ECM) to generate soluble 
cytokines, chemokines and growth factors together with their matching receptors. Considering 
that the regulation of the MMP-TIMP axis is also involved in the triggering of signal 
transduction pathways connected to DC functions, we provoked DC migration with an 
inflammatory cocktail or with poly(I:C) and could increase the expression level of MMP-9 
and MMP-12 in DC accompanied by decreased TIMP-1 and TIMP-2 expression showing a 
tight control of the inflammatory response. However, in the presence of MSCl cells, the 
expression level of TIMPs was dramatically upregulated and resulted in inhibited DC 
migration via blocking ECM degradation. More importantly, these effects could also modify 
the regulatory capacity of MMP by the secretion and proteolytic cleavage of cytokines and 
chemokines. Based on these results we conclude that MSCl cells are able to modulate the 
expression of key molecules infolved in DC migration. Moreover, the presence of MSCl cells 
 may also have an impact on the level and activity of secreted cytokines and chemokines, and 
also can affect the expression of their receptors for fine tuning DC activities in the actual 
inflammatory enviroment. 
 In vivo studies have revealed the inhibition of antigen specific effector T-cell 
functions in the course of mouse allograft rejection, in graft vs host disease, autoimmun 
encephyalomyelitis and collagen induced arthritis. In a murine model DC, conditioned by 
allogeneic MSC could inhibit MHC class I and II expression and inhibited antigen 
presentation by DC and decreased CD69 expression on CD8+ T-cells. In a human system, the 
presence of activated DC co-cultured with BM-MSC was shown to decrease the secretion of 
IFNγ by T cells. In the present study, the inhibited secretion of IFNγ could be detected by a 
sensitive ELISPOT assay. In this experimental setting human allogeneic T-lymphocytes, 
primed with activated DC and co-cultured with MSCl cells were able to down regulate T-cell 
polarization to the Th1 direction to a similar extent as DC co-cultured with BM-MSC. In our 
human in vitro studies MSC also could alter DC functions significantly, and together with our 
previous studies confirmed the potential of MSCl cells to exert inhibitory signals on antigen-
specific T-cell responses. In this context, the expression of RIG-like receptors has not been 
investigated so far. We hypothesized that the functional changes induced by the RLR ligand 
poly(I:C) are the consequence of the decreased expression of RLR. Our results indeed 
demonstrated that in the presence of MSCl cells the expression of RIG-I, MDA-5 and LGP-2 
in DC is dramatically impaired. Referring to the previously described partially activated DCs 
with tolerogenic and immune supressive properties MSCl cells may assist the maintenance of 
DC in a „semi-mature” supressive state. Our results obtained in a human system suggest that 
MSCl cells with unlimited proliferating capacity could be harnessed as a reliable model for 
inhibiting DC activation by MSC-mediated immune suppression. 
  
 6.  SUMMARY 
 
Dendritic cells (DCs) are constitutive sentinels of the immune system having the capacity to 
migrate across tissues. They are essential for linking innate and adaptive immune mechanisms 
through presenting antigenic peptides to naive T-lymphocytes. Baed on this potential DCs are 
increasingly used in immunotherapeutic interventions, predominantly in oncology and 
autoimmune disorders. Previous studies revealed phenotypic and functional differences of 
CD1a+ and CD1a- DC subpopulations associated with diverse functional activities in 
triggering inflammatory and/or regulatory type of immune responses, respectively. In the first 
part of our experimental work we have characterized the expression patterns of MMP 
enzymes and their TIMP inhibitors in monocytes and monocyte-derived DC subpopulations. 
MMP and TIMP have been identified as crucial players of preventing uncontrolled enzymatic 
degradation of the extracellular matrix known to be involved in the initiation of inflammation, 
autoimmune disorders and cancer metastasis via maintaining the balance of these opposing 
activities. As clinical trials aimed to prevent MMP enzyme activity were shown to decrease 
the spreading of cancer metastasis, we explored our studies by measuring the effects of 
GM6001, a wide spectrum MMP inhibitor without any influence on the phenotype of moDCs, 
on the migration of resting and activated DCs and on MMP and TIMP gene expression. In 
addition to the development of synthetic drugs and bioengineering, cell therapy approaches 
also became to the focus of interest.  
In the past few years MSC were considered as clinically important cell types due to their 
regenerative potential that can be utilized in cell therapies aimed to treat inflammatory and 
autoimmune disorders or apply them for tissue engineering. This approach is supported by the 
unique capability of MSC to bypass MHC compatibility for inducing immunosuppression. 
However, application of these cells for therapeutic interventions is limited due to the low 
number of MSC available. To overcome this restriction several groups also explored new 
strategies for identifying cell lines with immune suppressive properties. 
In the second phase of our work we have characterized the suppressive effects of MSC-like 
cells (MSCl) on the differentiation, activation and migration of activated DCs. We determined 
for the first time that in the presence of MSCl cells the expression level of TIMPs was 
dramatically upregulated and resulted in inhibited DC migration via blocking ECM 
degradation. More importantly, these effects could also modify the regulatory capacity of 
MMP by the secretion and proteolytic cleavage of cytokines and chemokines. Based on these 
results we conclude that MSCl cells are able to modulate the expression of key molecules 
 involved in DC migration. To clarify the possible involvement of the RLR family proteins we 
hypothesized that the functional changes induced by the RLR ligand poly(I:C) are the 
consequence of the decreased expression of RLR. Our results indeed demonstrated that in the 
presence of MSCl cells the expression of RIG-I, MDA-5 and LGP-2 in DCs is dramatically 
impaired. Referring to the previously described partially activated DCs with tolerogenic and 
immune suppressive properties, MSCl cells may assist the maintenance of DC in a „semi-
mature” suppressive state. Our results obtained in a human in vitro system suggest that MSCl 
cells with unlimited proliferating capacity could be harnessed as a reliable model for 
inhibiting DC activation by MSCl cell-mediated immune suppression. 
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